Virus News and Research

Latest Virus News and Research

Cell signaling hormone boosts immune response to clear HIV-like infection

Australian scientists have successfully cleared a HIV-like infection from mice by boosting the function of cells vital to the immune response.

4 Feb 2011

Tacere announces reacquisition of HCV compound development, commercialization rights in Asia

Tacere Therapeutics, an RNA interference (RNAi)-based therapeutics company, announced today that it has reacquired the development and commercialization rights to its Hepatitis C Virus compounds throughout Asia from its strategic partner, Tokyo-based Oncolys BioPharma Inc.

4 Feb 2011

FIND, Cepheid collaborate to develop rapid molecular test for measurement of HIV viral load

Cepheid and FIND today announced a new collaboration to accelerate the development of a rapid molecular test for the measurement of human immunodeficiency virus viral load.

3 Feb 2011

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Ceregene, a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.

3 Feb 2011

NIST team demonstrates a method for controlling different-sized nanoparticle production

The same properties that make engineered nanoparticles attractive for numerous applications-small as a virus, biologically and environmentally stabile, and water-soluble-also cause concern about their long-term impacts on environmental health and safety.

3 Feb 2011

First therapeutic vaccine designed from dendritic cells of patient achieves significant response

The therapeutic vaccines are a priority research line of the HIVACAT, the catalan programme for the development of therapeutic vaccines and prevention against the Human Immunodeficiency Virus (HIV). This type of therapeutic vaccine helps the patients who are carriers of the virus, combat infection and control the appearance of AIDS in the same way as with the current antiretroviral treatments.

3 Feb 2011

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the clinical study, SINGLE (ING114467), designed to support a new fixed-dose combination (FDC) therapy for the treatment of HIV.

3 Feb 2011

Losartan improves effectiveness of nanotherapeutics against cancer

Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid tumors, improved the effectiveness of two nanotherapeutics against several types of cancer.

3 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

African first ladies gather to discuss HIV/AIDS

On the sidelines of the African Union Summit in Addis Ababa, Ethiopia, on Monday, the General Assembly of the Organization of African First Ladies Against HIV/AIDS (OAFLA) gathered to discuss the continent's progress against HIV/AIDS, Walta Info reports.

3 Feb 2011

Study finds recurrences of shingles prevalent in the immunocompetent population

For decades, medical wisdom about shingles has been that it's a once-in-a-lifetime experience. The commonly-held belief is that patients are protected from a recurrence of the herpes zoster virus, which causes shingles, after one episode. But according to a study published in the February issue of Mayo Clinic Proceedings, recurrences of shingles may be significantly more common than doctors have suspected.

2 Feb 2011

Size of influenza-laden particles linked to risk of infection

A parent's wise advice to never go to a hospital unless you want to get sick may be gaining support from scientific studies on a specific airborne virus.

2 Feb 2011

Bill Gates' annual letter calls for focus on eradicating polio, governments to sustain foreign aid

Bill Gates, co-chair of the Bill & Melinda Gates Foundation, "urged developed nations to help him wipe out polio 'once and for all' at an event to release his third annual letter [.pdf] Monday," Agence France-Presse reports.

2 Feb 2011

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

A targeted delivery combination selectively crosses the tight barrier that protects the brain from the bloodstream to home in on and bind to brain tumors, a research team led by scientists from The University of Texas MD Anderson Cancer Center reported in the January issue of the Journal of Clinical Investigation.

2 Feb 2011

New research: HIV-infected youth get pregnant more often, suffer complications frequently

Teenage girls and young women infected with HIV get pregnant more often and suffer pregnancy complications more frequently than their HIV-negative peers, according to new research led by Johns Hopkins investigators.

2 Feb 2011

Surge of mosquito borne disease in South Australia following wet weather

Rising water in the Murray River has caused a surge in mosquito-borne infections in South Australia. The water is rising in the Murray in SA as floodwaters move downstream from the eastern states.

2 Feb 2011

Scientists test new dry powder measles vaccine that can be inhaled

Sustained high vaccination coverage is key to preventing deaths from measles. Despite the availability of a vaccine, measles remains an important killer of children worldwide, particularly in less-developed regions where vaccination coverage is limited. A team of researchers, led by scientists at the Johns Hopkins Bloomberg School of Public Health and the University of Colorado, developed and successfully tested a dry powder, live-attenuated measles vaccine that can be inhaled.

2 Feb 2011

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Medicago, a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.

1 Feb 2011

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

1 Feb 2011

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2010 results.

1 Feb 2011

Virus News and Research

Latest Virus News and Research

Cell signaling hormone boosts immune response to clear HIV-like infection

Tacere announces reacquisition of HCV compound development, commercialization rights in Asia

FIND, Cepheid collaborate to develop rapid molecular test for measurement of HIV viral load

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

NIST team demonstrates a method for controlling different-sized nanoparticle production

First therapeutic vaccine designed from dendritic cells of patient achieves significant response

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Losartan improves effectiveness of nanotherapeutics against cancer

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

African first ladies gather to discuss HIV/AIDS

Study finds recurrences of shingles prevalent in the immunocompetent population

Size of influenza-laden particles linked to risk of infection

Bill Gates' annual letter calls for focus on eradicating polio, governments to sustain foreign aid

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

New research: HIV-infected youth get pregnant more often, suffer complications frequently

Surge of mosquito borne disease in South Australia following wet weather

Scientists test new dry powder measles vaccine that can be inhaled

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in